Table 2.
Exposure and Administration Details
| Characteristic | In Utero–Exposed Newborns (n = 43) | Preterm Infants (n = 80) |
|---|---|---|
| Source of VZV exposure | ||
| In utero | 43 (100) | 0 |
| Hospital | 0 (0) | 79 (99) |
| Household | 0 (0) | 1 (1) |
| Type of VZV exposurea | ||
| Varicella | 26 (60) | 26 (33) |
| Herpes zoster | 6 (14) | 20 (25) |
| Not specified | 11 (26) | 34 (42) |
| Timing of administrationb | ||
| ≤96 hours postexposure | 37 (86) | 71 (89) |
| >96 hoursc postexposure | 6 (14) | 8 (10) |
| Unknown | 0 (0) | 1 (1) |
| Concomitant antiviral prophylaxis | ||
| Did not receive | 32 (74) | 77 (96) |
| Did receive | 11 (26) | 3 (4) |
Data are presented as No. (%).
Abbreviation: VZV, varicella zoster virus.
aFor in utero–exposed newborns, the type of VZV exposure refers to the maternal VZV infection.
bTiming of administration is calculated based on initial report of exposure. For in utero–exposed infants, this was considered to have occurred at birth or prior to birth.
cTiming of administration was >96 hours (up to 10 days) postexposure.